Human interleukin-2
- Generic Name
- Human interleukin-2
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- FNO32LO217
- Background
Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).
- Associated Conditions
- -
- Associated Therapies
- -
Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive Chemotherapy
Phase 1
Completed
- Conditions
- Breast NeoplasmNeoplasm Metastasis
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 51
- Registration Number
- NCT00001440
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Pharmacodynamics of Intermittent IL-2 Infusions in HIV Seropositive Patients
Phase 2
Completed
- Conditions
- HIV Infection
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 36
- Registration Number
- NCT00001474
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
Subcutaneously Administered Interleukin-2 Therapy in HIV-Infected Patients
Phase 2
Completed
- Conditions
- HIV Infection
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 80
- Registration Number
- NCT00001357
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
Home Treatment of HIV-Infected Patients With Interleukin-2 With or Without a Tumor Necrosis Factor Antagonist
Phase 2
Completed
- Conditions
- Acquired Immunodeficiency SyndromeHIV Infection
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 85
- Registration Number
- NCT00001475
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
Genetically Modified Lymphocytes to Treat HIV-Infected Identical Twins - Study Modifications
Phase 1
Completed
- Conditions
- Acquired Immunodeficiency SyndromeHIV Infection
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 100
- Registration Number
- NCT00001409
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath